The move leaves J&J focused on its pharmaceutical and MedTech segments, which make prescription drugs, contact lenses and technology to treat cardiovascular disease and help with surgeries.
Elanco opened the doors of its new headquarters at the former GM stamping plant site this week.
The new vitamin D test, to be distributed from the Swiss-based company’s Indianapolis hub, is the first such test using a mass spectrometry-based system to receive regulatory approval in the U.S.
Evidence from clinical trials shows that GLP-1s have benefits beyond weight loss, preventing related chronic conditions and ultimately blunting health-plan costs. But the savings might take decades, experts say.
Ag giant Corteva Agriscience is reportedly mulling a split of its seed and pesticide businesses, a move that could alter the company’s presence in Indianapolis as well as the state’s agriculture industry.
The sales momentum comes as Elanco prepares to open its $200 million-plus corporate campus next month on the west side of downtown Indianapolis.
Gayle Cook was known for her work in historic preservation—most notably for spearheading the restoration and preservation of the West Baden Springs and French Lick resorts.
Elanco Animal Health last week released what CEO Jeff Simmons called its best quarterly earnings since its 2018 spinoff from Eli Lilly and Co.
Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes and obesity.
The company, which makes vaccines, antibiotics and other animal-health products, said it now expects full-year revenue of between $4.57 billion and $4.62 billion.
Indiana University School of Medicine researcher Jeff Dage’s years of research into biomarkers helped lead to a first-of-its-kind blood test to diagnose Alzheimer’s disease.
Boston-based Verve Therapeutics is a Nasdaq-traded company focused on genetic medicines for cardiovascular disease.
Chief Scientific Officer Dr. Daniel Skovronsky talked with the IBJ about his hopes for the Lilly Medicine Foundry, which the Indianapolis-based drugmaker broke ground on this week.
Officials from the Indianapolis-based drugmaker said the Lilly Medicine Foundry will help streamline the process of discovering new medicines and getting them to patients.
In addition, IU LAB announced that its accelerator programs will now be called IU Health Incubator at IU LAB, thanks to a $4.5 million, three-year sponsorship deal with IU Health.
Roche said Indiana would receive a new manufacturing facility for continuous glucose monitoring and expansion and upgrades at existing pharmaceutical, diagnostics and distribution operations.
The pre-clinical West Lafayette-based medical device startup is working to develop a new “microstructred” catheter to remove blood clots that cause strokes.
The LEAP Research and Innovation District, led by the Indiana Economic Development Corp., is among the costliest economic development projects Indiana has attempted. But the agency’s structure obscures its spending and who benefits.
Indianapolis-based Gate Neurosciences, which is in clinical trials of a medicine to treat depression, plans to acquire California-based biotech startup Boost Neuroscience.
The National Institutes of Health said the change would save more than $4 billion a year, effective immediately.
